Display options
Share it on

Curr Treat Options Neurol. 2004 May;6(3):209-219. doi: 10.1007/s11940-004-0013-8.

Restless Legs Syndrome.

Current treatment options in neurology

Suzanne Lesage, Christopher J. Earley

Affiliations

  1. Department of Neurology, Johns Hopkins Bayview Medical Center and the Johns Hopkins Center for Restless Legs Syndrome, 5501 Hopkins Bayview Circle, AAC-1B-82, Baltimore, MD 21224, USA. [email protected]

PMID: 15043804 DOI: 10.1007/s11940-004-0013-8

Abstract

In the past 10 years, restless legs syndrome (RLS) has gained recognition as a common sleep disorder. There are several therapeutic options in treating patients with RLS. RLS causes significant sleep disturbance and negatively impacts on patient quality of life. Pharmacologic treatment can result in improved sleep and quality of life issues. RLS patients should be evaluated for iron deficiency anemia; iron replacement in deficient patients may lead to a resolution of symptoms or may reduce the severity of their symptoms. For patients with daily symptoms, the initial therapy is dopamine agonists. Low doses given in the evening or 2 hours before bed provide adequate relief of symptoms for many RLS patients. Augmentation can be seen with all dopamine agents, but is most prevalent with levodopa. Levodopa therapy is best used for milder intermittent symptoms or in aggravating situations, such as long car rides. Opiates and antiepileptics remain a beneficial therapy for RLS and are useful in patients who experience pain as part of their RLS. Newer anticonvulsants may provide additional treatment options, but they have yet to undergo clinical trials. Intravenous iron also may provide relief of RLS symptoms; however, dosing and safety issues have not been fully evaluated in a RLS population.

References

  1. Am J Kidney Dis. 1996 Sep;28(3):372-8 - PubMed
  2. J Womens Health Gend Based Med. 2001 May;10(4):335-41 - PubMed
  3. Neuropsychobiology. 2003;48(2):82-6 - PubMed
  4. Arch Intern Med. 2000 Jul 24;160(14):2137-41 - PubMed
  5. N Engl J Med. 2003 May 22;348(21):2103-9 - PubMed
  6. Arch Neurol. 1990 Nov;47(11):1223-4 - PubMed
  7. Br Med J (Clin Res Ed). 1984 Feb 11;288(6415):444-6 - PubMed
  8. Neurology. 2002 Nov 26;59(10):1573-9 - PubMed
  9. Sleep. 2002 Mar 15;25(2):213-8 - PubMed
  10. Sleep. 1998 Jun 15;21(4):371-7 - PubMed
  11. Neurology. 2002 Feb 26;58(4 Suppl 1):S87-92 - PubMed
  12. Am J Kidney Dis. 2001 Jul;38(1):104-8 - PubMed
  13. Pediatr Neurol. 2000 Mar;22(3):182-6 - PubMed
  14. Age Ageing. 1994 May;23(3):200-3 - PubMed
  15. Mov Disord. 2003 Oct;18(10):1184-9 - PubMed
  16. Brain. 2003 Jun;126(Pt 6):1485-92 - PubMed
  17. Am J Hum Genet. 2001 Dec;69(6):1266-70 - PubMed
  18. J Neural Transm (Vienna). 2003 Jun;110(6):611-26 - PubMed
  19. Neurology. 1999 Mar 23;52(5):938-43 - PubMed
  20. Mov Disord. 1999 Jan;14(1):138-40 - PubMed
  21. Neurology. 2001 May 22;56(10):1399-402 - PubMed
  22. Sleep. 1996 Apr;19(3):205-13 - PubMed
  23. J Psychosom Res. 2002 Jul;53(1):547-54 - PubMed
  24. Sleep. 1999 Dec 15;22(8):1073-81 - PubMed
  25. Mov Disord. 2001 May;16(3):577-9 - PubMed
  26. Sleep. 1994 Dec;17(8):739-43 - PubMed
  27. Am J Med. 1996 Mar;100(3):333-7 - PubMed
  28. Sleep Med. 2003 Mar;4(2):101-19 - PubMed
  29. Psychiatry Res. 2002 Aug 20;115(1-2):49-61 - PubMed
  30. Mov Disord. 2002 Sep;17(5):1072-6 - PubMed
  31. Mov Disord. 2001 Nov;16(6):1105-9 - PubMed
  32. Sleep. 1993 Jun;16(4):327-32 - PubMed
  33. Med Sci Monit. 2002 May;8(5):CR331-6 - PubMed
  34. Sleep. 1993 Dec;16(8):717-23 - PubMed
  35. Sleep. 1999 Nov 1;22(7):970-99 - PubMed
  36. Sleep. 1998 Sep 15;21(6):617-22 - PubMed
  37. Sleep Med. 2002 Mar;3(2):127-32 - PubMed
  38. Sleep. 2003 Nov 1;26(7):819-21 - PubMed
  39. Sleep. 1997 Oct;20(10):878-82 - PubMed
  40. Eur Neurol. 2002;48(3):180-1 - PubMed
  41. Neurology. 1998 Dec;51(6):1599-602 - PubMed
  42. Neurology. 1960 Sep;10:868-73 - PubMed
  43. Neurology. 1999 Mar 23;52(5):944-50 - PubMed
  44. Wien Med Wochenschr. 1995;145(17-18):525-7 - PubMed

Publication Types